IgA as therapeutic antibody
Files
Publication date
2015-11
Authors
Leusen, Jeanette H.W.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e. polymorphonuclear cells or neutrophils, but can also activate monocytes and macrophages. The present knowledge, but also future direction for IgA- based drugs are discussed.
Keywords
Animals, Antigens, CD20, Antineoplastic Agents, B-Lymphocytes, Gene Expression, Humans, Immunization, Passive, Immunoglobulin A, Immunoglobulin G, Lymphocyte Depletion, Macrophages, Mice, Monocytes, Neoplasms, Neutrophils, Rituximab, Antibody therapy, IgA, Immunotherapy, Taverne, Journal Article, Research Support, Non-U.S. Gov't, Review
Citation
Leusen, J H W 2015, 'IgA as therapeutic antibody', Molecular Immunology, vol. 68, no. 1, pp. 35-9. https://doi.org/10.1016/j.molimm.2015.09.005